Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1-Infected Individuals

被引：74

作者：

Yilmaz, Aylin ^{[1
]}

Izadkhashti, Arash ^{[1
]}

Price, Richard W. ^{[2
]}

Mallon, Patrick W. ^{[3
]}

De Meulder, Marc ^{[4
]}

Timmerman, Philip ^{[4
]}

Gisslen, Magnus ^{[1
]}

机构：

[1] Univ Gothenburg, Sahlgrenska Acad, Dept Infect Dis, Gothenburg, Sweden

[2] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurol, San Francisco, CA 94110 USA

[3] Mater Misericordiae Univ Hosp, Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland

[4] Jonhson & Johnson Pharmaceut Res & Dev, Beerse, Belgium

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2009年 / 25卷 / 04期

基金：

美国国家卫生研究院;

关键词：

CENTRAL-NERVOUS-SYSTEM; ACTIVE ANTIRETROVIRAL THERAPY; AIDS DEMENTIA COMPLEX; HIV-1; INFECTION; VIRAL LOAD; LOPINAVIR CONCENTRATIONS; COMBINATION THERAPY; DRUG CONCENTRATIONS; IMMUNE ACTIVATION; RNA;

D O I：

10.1089/aid.2008.0216

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Darunavir is the most recently licensed protease inhibitor currently used in treatment-experienced HIV-infected individuals. Our objective was to determine darunavir concentrations in cerebrospinal fluid (CSF) and plasma in subjects receiving antiretroviral treatment regimens containing ritonavir-boosted darunavir. Darunavir concentrations were determined by liquid chromatography tandem mass spectrometry in 14 paired CSF and plasma samples from eight HIV-1-infected individuals. The lower limit of quantification was 5.0 ng/ml. All of the 14 CSF samples had detectable darunavir concentrations with a median darunavir concentration of 34.2 ng/ml (range 15.9-212.0 ng/ml). The median (range) plasma darunavir concentration was 3930 (1800-12900) ng/ml. All CSF samples had detectable darunavir concentrations. Most of them exceeded or were in the same range as levels needed to inhibit replication of wild type virus, making it probable that darunavir, at least to some extent, contributes to the suppression of HIV replication in the central nervous system.

引用

页码：457 / 461

页数：5

共 33 条

[1]

[Anonymous], 15 C RETR OPP INF BO

[2] Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex [J].

Aweeka, F ;

Jayewardene, A ;

Staprans, S ;

Bellibas, SE ;

Kearney, B ;

Lizak, P ;

Novakovic-Agopian, T ;

Price, RW .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (01) :39-43

[3] PENETRATION OF ZIDOVUDINE INTO THE CEREBROSPINAL-FLUID OF PATIENTS INFECTED WITH HIV [J].

BURGER, DM ;

KRAAIJEVELD, CL ;

MEENHORST, PL ;

MULDER, JW ;

KOKS, CHW ;

BULT, A ;

BEIJNEN, JH .

AIDS, 1993, 7 (12) :1581-1587

[4] Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV [J].

Capparelli, EV ;

Holland, D ;

Okamoto, C ;

Gragg, B ;

Durelle, J ;

Marquie-Beck, J ;

van den Brande, G ;

Ellis, R ;

Letendre, S .

AIDS, 2005, 19 (09) :949-952

[5] Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:: a pooled subgroup analysis of data from two randomised trials [J].

Clotet, Bonaventura ;

Bellos, Nicholas ;

Molina, Jean-Michel ;

Cooper, David ;

Goffard, Jean-Chrostophe ;

Lazzarin, Adriano ;

Woehrmann, Andrej ;

Katlama, Christine ;

Wilkin, Timothy ;

Haubrich, Richard ;

Cohen, Calvin ;

Farthing, Charles ;

Jayaweera, Dushyantha ;

Markowitz, Martin ;

Ruane, Peter ;

Spinosa-Guzman, Sabrina ;

Lefebvre, Eric .

LANCET, 2007, 369 (9568) :1169-1178

[6]

de Jesus E, 2007, 47 INT C ANT AG CHEM

[7] TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates [J].

De Meyer, S ;

Azijn, H ;

Surleraux, D ;

Jochmans, D ;

Tahri, A ;

Pauwels, R ;

Wigerinck, P ;

de Béthune, MP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2314-2321

[8] Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy [J].

Eden, Arvid ;

Price, Richard W. ;

Spudich, Serena ;

Fuchs, Dietmar ;

Hagberg, Lars ;

Gisslen, Magnus .

JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (12) :1779-1783

[9] Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration [J].

Eggers, C ;

Hertogs, K ;

Stürenburg, H ;

van Lunzen, J ;

Stellbrink, HJ .

AIDS, 2003, 17 (13) :1897-1906

[10] Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine [J].

Foudraine, NA ;

Hoetelmans, RMW ;

Lange, JMA ;

de Wolf, F ;

van Benthem, BHB ;

Mass, JJ ;

Keet, IPM ;

Portegies, P .

LANCET, 1998, 351 (9115) :1547-1551

← 1 2 3 4 →